Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04
LexBlog IP
FEBRUARY 23, 2024
On February 15, Alvotech announced that it reached more settlement agreements with Johnson & Johnson for ATV04, Alvotech’s biosimilar to STELARA (ustekinumab). Alvotech also announced that it expects to launch AVT04 in Q1 2024 in Canada, May 2024 in Japan, and late July 2024 in the European Economic Area.
Let's personalize your content